 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | UMC01 / Ever Supreme Bio Tech
Trial completion date, Trial primary completion date: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke (clinicaltrials.gov) - Sep 20, 2024
P1, N=14, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- || UMC01 / Ever Supreme Bio Tech
Trial completion date, Trial primary completion date: UMSC01: Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19 (clinicaltrials.gov) - Aug 28, 2024
P1/2, N=75, Active, not recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- | UMC01 / Ever Supreme Bio Tech
Trial completion date, Trial primary completion date: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke (clinicaltrials.gov) - Aug 14, 2023
P1, N=14, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- || UMC01 / Ever Supreme Bio Tech
Enrollment open, Trial initiation date: UMSC01: Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 10, 2023
P1/2, N=41, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Jun 2023
- || UMC01 / Ever Supreme Bio Tech
New P1/2 trial: UMSC01: Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Sep 8, 2022
P1/2, N=41, Not yet recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
- || UMC01 / Ever Supreme Bio Tech
Trial completion, Trial completion date: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction (clinicaltrials.gov) - Sep 8, 2022
P1, N=10, Completed, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Jun 2023 Recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2021
- || UMSC01 / Ever Supreme Bio Tech
P1 data, Journal: First-in-human pilot trial of combined intracoronary and intravenous mesenchymal stem cell therapy in acute myocardial infarction. (Pubmed Central) - Aug 27, 2022
This pilot study shows that combined IC and IV transplantation of UMSC01 in STEMI patients with impaired LVEF appears to be safe, feasible, and potentially beneficial in improving heart function. Further phase 2 studies are required to explore the effectiveness of dual-route transplantation of UMSC01 in STEMI patients.
- |||| UMC01 / Ever Supreme Bio Tech
New P1/2 trial: UMSC01: Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19 (clinicaltrials.gov) - Aug 15, 2022
P1/2, N=75, Active, not recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
- | UMC01 / Ever Supreme Bio Tech
Trial completion date, Trial primary completion date: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke (clinicaltrials.gov) - Mar 23, 2022
P1, N=14, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Further phase 2 studies are required to explore the effectiveness of dual-route transplantation of UMSC01 in STEMI patients. Trial completion date: Sep 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Dec 2023
- | UMC01 / Ever Supreme Bio Tech
Trial completion date, Trial primary completion date: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction (clinicaltrials.gov) - Feb 2, 2021
P1, N=8, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Trial completion date: Sep 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Dec 2023 Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- || UMC01 / Ever Supreme Bio Tech
New P1 trial: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke (clinicaltrials.gov) - Jun 16, 2020
P1, N=14, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
- | UMC01 / Ever Supreme Bio Tech
New P1 trial: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction (clinicaltrials.gov) - Aug 13, 2019
P1, N=8, Recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
- | UMC01 / Ever Supreme Bio Tech
Trial completion date, Trial initiation date, Trial primary completion date: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells With Acute Myocardial Infarction (clinicaltrials.gov) - Apr 10, 2018
P1, N=8, Not yet recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.
Trial completion date: Aug 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial completion date: Dec 2021 --> Aug 2020 | Initiation date: Jul 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Aug 2019
- | UMC01 / Ever Supreme Bio Tech
New P1 trial: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells With Acute Myocardial Infarction (clinicaltrials.gov) - Mar 11, 2018
P1, N=8, Not yet recruiting, Sponsor: Ever Supreme Bio Technology Co., Ltd.